Loading clinical trials...
Loading clinical trials...
A Phase Ia/b Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending Doses of AZD3427 in Healthy Volunteers and Multiple Ascending Doses of AZD3427 in Patients With Heart Failure (HFrEF and HF With EF ≥ 41%)
Conditions
Interventions
AZD3427
Placebo
Locations
10
United States
Research Site
Little Rock, Arkansas, United States
Research Site
Glendale, California, United States
Research Site
Daytona Beach, Florida, United States
Research Site
Doral, Florida, United States
Research Site
Hallandale, Florida, United States
Research Site
Jacksonville, Florida, United States
Start Date
November 17, 2020
Primary Completion Date
September 14, 2022
Completion Date
September 14, 2022
Last Updated
October 20, 2022
NCT07083011
NCT07550790
NCT07037459
NCT06148935
NCT06874556
NCT06741436
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions